Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.66, compared with -$1.03 a year earlier. Trailing-twelve-month EPS (Diluted) was -$3.28.
Context
- EPS (Diluted) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$2.87 (+21.3%) for the fiscal year ending Dec 2026, a step up from the -9.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.66+17.5% QoQ
- Last fiscal yearDec 2025
- -$3.64-9.3% YoY
- LTMMar 2026
- -$3.28+2.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +35.9% | +30.1% | -5.9 pp |
| 1 year | -9.3% | +21.3% | +30.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (3.64) USD
- Year-over-year change
- -9.3%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.64) | -9.3% |
| FY2024 | 2024-12-31 | (3.33) | -3329900.0% |
| FY2023 | 2023-12-31 | (0.00) | +100.0% |
| FY2022 | 2022-12-31 | (1.12) | -9.8% |
| FY2021 | 2021-12-31 | (1.02) | — |
EPS (Diluted) vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 EPS (Diluted) of -$3.28 is the 9th highest of the 11 companies compared; the peer median is -$1.96.
- Its year-over-year change of +2.7% is the 6th highest of 10, against a peer median of +23.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.22 | +99.9% | — | |
| LTM Mar 2026 | -$0.77 | +37.4% | — | |
| LTM Mar 2026 | -$1.23 | +59.6% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$1.45 | +56.1% | — |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | -$1.95 | -1.0% | — |
| LTM Mar 2026 | -$1.97 | +23.0% | — | |
| LTM Mar 2026 | -$2.11 | -27.9% | — | |
| LTM Mar 2026 | -$2.32 | -63.4% | — | |
| LTM Mar 2026 | -$3.28 | +2.7% | — | |
| LTM Mar 2026 | -$4.32 | — | — | |
| LTM Mar 2026 | -$12.74 | -919.7% | — | |
| Peer median (excluding KYTX) | -$1.96 | +23.0% | — | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| Weighted Avg Shares | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
| Weighted Avg Shares (Diluted) | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.